Sign Up For Free
Despite evidence that some active substances in cannabis may support some aspects of health, many people who use this drug, and particularly those who smoke it, can develop symptoms of dependence. A new clinical trial shows that a safer, cannabis-based medication can counter this dependence.

The National Institute on Drug Abuse notes that about 30% of recreational cannabis users in the United States "may have some degree of marijuana use disorder" that symptoms of dependence often characterize. 

Dependence causes a person to compulsively seek the drug as they experience withdrawal symptoms when they do not have access to it. Irritability, sleep problems, and poor appetite can be among these symptoms.

Researchers from Australia’s University of Sydney and New South Wales Ministry of Health point out that existing treatments for cannabis dependence are not always effective.

To address this issue, the team tested a new medicinal drug that is meant to be more effective in treating cannabis dependence than existing therapies.

In a new clinical trial — whose results the researchers report in JAMA Internal Medicine — they assessed the drug's effectiveness and safety for humans. This new medication is a cannabinoid agonist drug consisting of a cannabis extract that works by interacting with cannabinoid receptors in the brain.

These receptors are part of the endocannabinoid system, and their main role is to synthesize the substances that form part of ingested cannabis. By targeting them, the researchers hope to reduce the rate of relapse of people who seek treatment for cannabis dependence.

"We've never had the evidence before that medication can be effective in treating cannabis dependency — this is the first big study to show this is a safe and effective approach," says lead author Professor Nick Lintzeris.

"The principles are very similar to nicotine replacement; you are providing patients with a medicine, which is safer than the drug they're already using, and linking this with medical and counseling support to help people address their illicit cannabis use," Prof. Lintzeris explains.

Prof. Lintzeris and team tested this drug in 128 volunteers — 30 women and 98 men — with a mean age of 35 years. All the participants were recreational cannabis users who had sought treatment for dependence but who had previously been unsuccessful in stopping their recreational drug use.The researchers gave the nabiximols medication to the participants over 12 weeks. The users administered the drug in spray form, delivering it orally, under the tongue. The researchers gave each participant an average dose of 18 sprays per day; each spray was 0.1 milliliters, containing 2.7 milligrams (mg) of THC and 2.5 mg of CBD.

Prof. Lintzeris and his team followed up with the participants at baseline, and then again after two, 4, eight, and 12 weeks. Throughout the trial period, the participants also had cognitive behavioral therapy(CBT) and other forms of therapeutic support, as necessary.

The current results come hot on the heels of another study that the same research team led, which showed that nabiximols effectively reduced cannabis withdrawal symptoms in a short-term, in-hospital treatment program. 

However, the latest study, "is even more important in that it shows that nabiximols can be effective in helping patients achieve longer term changes in their cannabis use," Prof. Lintzeris emphasizes.

"Our study is an important step in addressing the lack of effective treatments — currently, four in five patients relapse to regular use within six months of medical or psychological interventions," he continued.

Source: https://www.medicalnewstoday.com/articles/325775.php

This article is now marked as read.

Was this article helpful?

Review this article to help us continue creating and sharing relevant content.

Please note it may take up to two business days for reviews to be validated and published.


Review this article to help us continue creating and sharing relevant content.

Write Review

Would you like to
make this review public?

Please disable your ad blocker to avoid issues using social plugins on Cannvas.Me. Thanks.